CureVac N.V. (CVAC)
NASDAQ: CVAC · IEX Real-Time Price · USD
3.720
+0.080 (2.20%)
At close: Jul 26, 2024, 4:00 PM
3.760
+0.040 (1.08%)
After-hours: Jul 26, 2024, 6:49 PM EDT
CureVac Revenue
CureVac had revenue of 12.37M EUR in the quarter ending March 31, 2024, with 73.56% growth. This brings the company's revenue in the last twelve months to 59.00M, up 17.59% year-over-year. In the year 2023, CureVac had annual revenue of 53.76M, down -20.26%.
Revenue (ttm)
59.00M EUR
Revenue Growth
+17.59%
P/S Ratio
13.01
Revenue / Employee
50,343 EUR
Employees
1,172
Market Cap
834.42M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
InnovAge Holding | 741.33M |
Cytek Biosciences | 200.79M |
Standard BioTools | 126.76M |
Simulations Plus | 66.98M |
Mesoblast | 7.25M |
Dianthus Therapeutics | 2.26M |
Perspective Therapeutics | -304.00K |
CVAC News
- 15 days ago - CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech - Accesswire
- 15 days ago - Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer - Business Wire
- 23 days ago - GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines - Barrons
- 23 days ago - CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines - Market Watch
- 23 days ago - GSK and CureVac to Restructure Collaboration into New Licensing Agreement - Accesswire
- 23 days ago - CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities - Accesswire
- 23 days ago - GSK buys full rights to make COVID, influenza vaccines from CureVac - Reuters
- 4 weeks ago - CureVac Announces Voting Results of General Meeting - Accesswire